findmyKOL
Clinical trialNCT00403325CompletedPhase 1Interventional

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

SponsorVitreous -Retina- Macula Consultants of New YorkEnrollment9Central Serous Chorioretinopathy
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Vitreous Retina Macula Consultants of New York, P.C.

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

RhuFab V2 [ranibizumab]
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2006
Primary completion
—
Completion
—
Last update posted
3 Nov 2008
Registered enrollment
9
Registry id
NCT00403325
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.